HK Stock Market Move | CARSGEN-B (02171) rose over 9% against the market trend as Kailemei became the first solid tumor CAR-T product in the commercial insurance innovative drug catalog.

date
10:33 17/11/2026
avatar
GMT Eight
CARSGEN-B (02171) rose over 9% against the market trend. As of press time, it was up 7.08% at HK$10.74, with a turnover of HK$19.8707 million.
CARSGEN-B (02171) rose over 9% against the market trend. As of press time, it was up 7.08% at HK$10.74, with a turnover of HK$19.8707 million. On the news front, on November 14, the 2026 commercial health insurance innovative drug catalog was announced. CARsgen Therapeutics' Kailemei (satri-cel injection) was included in the commercial insurance innovative drug catalog, becoming the first solid tumor CAR-T cell therapy product included since the catalog was established. Public information shows that Kailemei is the world's first-in-class autologous CAR-T cell therapy product targeting Claudin18.2 protein, and also the world's first approved solid tumor CAR-T cell therapy product. The drug was approved for marketing by the National Medical Products Administration in June 2026 for the treatment of advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) that is Claudin18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative, and has failed at least second-line therapy.